- Trials with a EudraCT protocol (933)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
933 result(s) found for: stem cell therapy.
Displaying page 1 of 47.
EudraCT Number: 2007-004928-21 | Sponsor Protocol Number: Auto-Allo-TSCTinMM | Start Date*: 2008-06-27 | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Autologous-Allogeneic Tandem Stem Cell Transplantation and Maintenance Therapy with Thalidomide / DLI for patients with Multiple Myeloma (MM) and age <= 60 years: A phase II-study | |||||||||||||
Medical condition: Multiple Myeloma Stage II or III according to Salmon and Durie | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000393-76 | Sponsor Protocol Number: ZKI-SCT-HAPLO-0106 | Start Date*: 2006-10-25 |
Sponsor Name:Johann Wolfgang Goethe-Universität Frankfurt am Main | ||
Full Title: Allogenic stem cell transplantation with CD3/CD19 depleted stem cells from haploidentical related and non-related donators in pediatric patients with and without malignant systemic diseases. | ||
Medical condition: Pediatric patients with malignant and non-malignant high-risk diseases, where the allogeneic stem cell transplantation represents the only option for a curative therapy and where an adequate HLA-id... | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2005-002657-45 | Sponsor Protocol Number: MSC1 | Start Date*: 2005-10-24 |
Sponsor Name:Cardiovascular laboratory 2014, Rigshospitalet | ||
Full Title: Mesenchymal stem cell therapy in patients with severe myocardial ischemia | ||
Medical condition: Chronic coronary artery disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-004499-47 | Sponsor Protocol Number: ZENITH | Start Date*: 2015-04-16 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA | |||||||||||||
Full Title: A case control, phase II, monocentric, randomized study, utilizing Zinc as enhancer of immune recovery and immune reconstitution in auto-transplant for multiple myeloma | |||||||||||||
Medical condition: Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001514-34 | Sponsor Protocol Number: ILNK15-01 | Start Date*: 2012-04-03 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Infusion of IL-15 activated NK cells after allogeneic stem cell transplantation in children transplanted for relapsed/refractory leukemia: a feasibility study | |||||||||||||
Medical condition: Children with high-risk and recurrent acute leukemia are eligible for allogeneic hematopoietic stem cell transplantation (HSCT). However, leukemia relapse and viral infections after HSCT remain mai... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000873-59 | Sponsor Protocol Number: Uni-Koeln-3263 | Start Date*: 2019-06-13 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: Consolidation Therapy with Brentuximab Vedotin after Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma | |||||||||||||
Medical condition: disease control after an allogeneic stem cell transplantation (alloSCT) for relapsed or refractory classical Hodgkin lymphoma (rrHL, cHL) with consolidation therapy by Brentuximab Vedotin (BV) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001005-67 | Sponsor Protocol Number: AlloRelapseMMStudy | Start Date*: 2022-05-11 | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy) | |||||||||||||
Medical condition: Multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005562-38 | Sponsor Protocol Number: M2011-238 | Start Date*: 2012-11-13 | |||||||||||
Sponsor Name:Miltenyi Biotec GmbH | |||||||||||||
Full Title: A multi-center phase I/II safety and feasibility study using CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for haematopoietic progenitor cell transplantation in chi... | |||||||||||||
Medical condition: Hematological and non-hematological malignancies, and non-malignant diseases, requiring allogeneic blood stem cell transplantation without available HLA-identical donor. | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004953-26 | Sponsor Protocol Number: BHS-TC13 | Start Date*: 2016-03-11 |
Sponsor Name:Ghent University Hospital | ||
Full Title: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor. | ||
Medical condition: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor. | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2013-000015-24 | Sponsor Protocol Number: 07MI05 | Start Date*: 2015-04-10 |
Sponsor Name:Great Ormond Street Hospital | ||
Full Title: 90-Yttrium-labelled anti-CD66 monoclonal antibody as part of a reduced intensity conditioning regimen prior to allogeneic haematopoietic stem cell transplantation: an open label, dose escalating ph... | ||
Medical condition: High risk relapsed or refractory leukaemia in childhood | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001911-38 | Sponsor Protocol Number: GELTAMOMAN2 | Start Date*: 2014-09-19 | |||||||||||
Sponsor Name:Grupo Español de Linfoma y Trasplante Autólogo de Médula ósea | |||||||||||||
Full Title: AN OPEN MULTICENTER PHASE II STUDY OF EFFICACY AND TOXICITY OF MAINTENANCE SUBCUTANEOUS RITUXIMAB AFTER RESCUE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA NON-ELIGIBLE FO... | |||||||||||||
Medical condition: PATIENTS WITH RELAPSED OR REFRACTORY MANTLE-CELL LYMPHOMA NON-ELIGIBLE FOR AUTO OR ALLO STEM CELL TRANSPLANTATION | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000290-23 | Sponsor Protocol Number: HULPVAS-2011-01 | Start Date*: 2013-02-06 |
Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario La Paz | ||
Full Title: Clinical trial phase IIa to safety treating critical ischemia non-revascularizable lower limb by mesenchymal stem cells. | ||
Medical condition: Treatment of critical limb ischemia non-revascularization by mesenchymal stem cells. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001790-86 | Sponsor Protocol Number: PIX306 | Start Date*: 2012-12-24 | ||||||||||||||||
Sponsor Name:CTI Biopharma, Corp. | ||||||||||||||||||
Full Title: A Randomized Multicenter Study Comparing Pixantrone + Rituximab with Gemcitabine + Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed after Therapy with CHOP-R or a... | ||||||||||||||||||
Medical condition: Treatment of Patients with Aggressive B-cell Non-Hodgkin Lymphoma , who Have Relapsed after Therapy with CHOP-R or an Equivalent Regimen and are Ineligible for Stem Cell Transplant | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) ES (Completed) DE (Completed) FR (Completed) HU (Completed) IT (Completed) CZ (Completed) DK (Prematurely Ended) BG (Prematurely Ended) PL (Completed) BE (Completed) AT (Completed) SK (Completed) RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-012437-30 | Sponsor Protocol Number: BUS‐2009/01 | Start Date*: 2010-06-17 |
Sponsor Name:Skånes University Hospital | ||
Full Title: Clofarabine based remission induction followed by haploidentical stem cell transplantation in children with refractory hematological malignancies | ||
Medical condition: Therapy resitant leukemia in children and young adults | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003683-54 | Sponsor Protocol Number: OSHO #76 | Start Date*: 2008-06-18 |
Sponsor Name:GMIHO Gesellschaft für medizinische Innovation/Hämatologie und Onkologie mbH | ||
Full Title: Prospektive, offene, randomisierte, multizentrische Studie zur Effektivität von Palifermin in der Prophylaxe der Mukositis nach allogener Stammzelltransplantation mit myeloablativer Granzkörperbest... | ||
Medical condition: Patients suffering from leukemia (acute or chronic), receiving allogenic blood stem cell transplantation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-000795-15 | Sponsor Protocol Number: MYVAC2 | Start Date*: 2014-01-29 | |||||||||||
Sponsor Name:UZ Brussel | |||||||||||||
Full Title: An open-label pilot clinical trial of MAGE-A3 and MAGE-C1 mRNA electroporated autologous dendritic cell vaccination in combination with lenalidomide maintenance therapy for multiple myeloma after f... | |||||||||||||
Medical condition: Symptomatic Multiple Myeloma after first-line autologous stem cell transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003033-42 | Sponsor Protocol Number: UKER-BLZ-PH1 | Start Date*: 2013-09-12 | |||||||||||
Sponsor Name:Universitätsklinikum Erlangen | |||||||||||||
Full Title: Prospective, open-label, multicentre clinical trial, phase I/IIa, to investigate the safety and tolerability of allogeneic B-cell concentrates CD3+-depleted, CD19+-enriched, cryopreserved (single a... | |||||||||||||
Medical condition: Status post allogeneic stem cell transplantation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024307-27 | Sponsor Protocol Number: LUMC2010-03 | Start Date*: 2011-11-01 |
Sponsor Name:Leiden University Medical Center | ||
Full Title: TREATMENT WITH CMV PP65-SPECIFIC T CELLS GENERATED BY USE OF A CMV PP65 PROTEIN-SPANNING PEPTIDE POOL IN PATIENTS WITH CMV REACTIVATION OR CMV DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION | ||
Medical condition: CMV reactivation after allogeneic stem cell transplantation | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-003523-30 | Sponsor Protocol Number: 38RC17.191 | Start Date*: 2017-12-18 | |||||||||||
Sponsor Name:University Hospital Grenoble | |||||||||||||
Full Title: Vaccination after hematopoietic stem cell transplantation : a randomized study estimating the interest of an additional injection for patients not reponding at M3. | |||||||||||||
Medical condition: Our aim is to determine whether an additional dose of inactivated vaccine can increase the rate of responders among patients who have not responded adequately after 3 injections | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000103-16 | Sponsor Protocol Number: RC13_0008 | Start Date*: 2013-06-21 | ||||||||||||||||
Sponsor Name:CHU de Nantes | ||||||||||||||||||
Full Title: Antifungal prophylaxis with Micafungin after cord blood allogeneic stem cell transplantation. | ||||||||||||||||||
Medical condition: Adult patients receiving allo-Stem Cell Transplantation using Cord Blood as source of stem cells | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
